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A Ab bs st tr ra ac ct t
Survival rates from colorectal cancer (CRC) differ dramatically according to the stage of the
tumor at diagnosis, with survival rates of 90% for patients with stage I disease but only 49% for
those with stage III cancer. Many serum and tumor markers have been identified but none has
provided a significant improvement over tumor stage as a prognostic indicator for cancer
recurrence for patients with stage II or III disease. Aberrant activation of the hepatocyte growth
factor (HGF)/HGF receptor (MET) signaling pathway is associated with both malignant
transformation and metastatic potential of CRC. MACC1 (metastasis-associated in colon cancer-1)
is a newly discovered gene that regulates this signaling cascade. The significant correlation
between overexpression of MACC1 in CRC and both malignant transformation and subsequent
risk for metastases in stage II and III CRC indicates that MACC1 tumor typing may prove valuable
for determining risk for CRC recurrence. MACC1 may also be an important therapeutic target
for CRC treatment.
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D De et te ec ct ti in ng g   c co ol lo or re ec ct ta al l   c ca an nc ce er r   r re ec cu ur rr re en nc ce e
To date, the most reliable prognostic indicator for colorectal
cancer (CRC) has been stage, but discerning which of those
patients with stage II or III disease will be among the 25-
51% of cases to develop recurrent cancer and succumb to
the disease remains one of the most problematic and
frustrating issues concerning clinical care and cancer
surveillance strategies for CRC patients. Recent guidelines
by the European Group of Tumor Markers for the clinical
use of CRC markers determined that currently only
measurement of serum carcinoembryonic antigen (CEA)
every two to three months may be of value for recognizing
recurrence in patients with stage II or III disease [1]. Other
serum markers, including cancer antigen CA19.9, CA242
and tissue inhibitor of metalloproteinases (TIMP-1), or the
tumor markers thymidylate synthase, microsatellite
instability, p53, K-ras, and deleted in colon cancer (DCC)
offer no advantage beyond the limited specificity and
sensitivity of CEA for early detection of cancer recurrence
[1]. Stein et al. [2] report the association of overexpression
of  MACC1 with an increased risk for CRC metastasis,
providing compelling data that this gene may be useful both
as a prognostic marker and possibly as a chemopreventive
or therapeutic target.
H He ep pa at to oc cy yt te e   g gr ro ow wt th h   f fa ac ct to or r   ( (H HG GF F) )   a an nd d   t th he e   H HG GF F
r re ec ce ep pt to or r   ( (M ME ET T) )
MACC1 is located on chromosome 7p21.1 and regulates
injury response and tissue growth via the HGF/MET signal-
ing pathway. Of note, HGF and MET also map to chromo-
some 7 (7q21.1 and 7q31, respectively). Polysomy of chromo-
some 7 is a common finding in both glioblastomas and CRC
tumors [3], and recent genome-wide analysis of siblings with
familial CRC not related to known genetic conditions
implicated 7q31 as a region linked to hereditary CRC [4].HGF regulates growth of liver sinusoidal endothelial cells
and interacts with interleukin 7 to regulate the immune
response to mucosal lymphocytes in the intestinal mucosa
[5], mainly via activity in the stroma. The malaria parasite
Plasmodium sporozoite stimulates stromal cell secretion of
HGF, which activates its receptor MET. Activation of
HGF/MET in turn disrupts the host-cell cytoskeleton,
making the hepatocytes vulnerable to infection with this
parasite [6]. HGF prompts tumor invasiveness via tumor-
stromal cell interactions. Increased stromal expression of
HGF is associated with many cancer types, including endo-
metrial and breast cancer [7,8].
MET is a proto-oncogene considered essential for metastatic
potential in CRC [9-12]. MET was first recognized as an
oncogene in osteosarcoma cell lines [13], and later Schmidt
et al. [14] detected missense mutations in the tyrosine kinase
domain of MET  both in the germline of individuals with
hereditary papillary renal carcinoma and in somatic DNA
from sporadic papillary renal carcinomas. MET is expressed
mainly on the surface of epithelial cancer cells. Missense
mutations in the tyrosine kinase domain of MET also have
been detected in childhood hepatocellular carcinomas [15].
MET encodes the tyrosine kinase that serves as a cell surface
receptor for HGF/scatter factor (HGF/SF), which is one
member of a family of soluble proteins known as scatter
factors that regulate invasive growth [16,17].
A Ac ct ti iv va at ti io on n   o of f   H HG GF F/ /M ME ET T   s si ig gn na al li in ng g   c ca an n   l le ea ad d   t to o   i in nv va as si iv ve e
g gr ro ow wt th h   a an nd d   c ca an nc ce er r
Aberrant activation of MET deregulates the HGF/MET
signaling pathway, leading to increased cell proliferation,
invasion and metastasis [18]. MET has multiple docking
sites, including a transducer docking site that intensifies
both the transforming and metastatic abilities of this
oncogene. HGF binding to MET leads to phosphorylation of
two tyrosine residues in the carboxyl terminus, which, once
phosphorylated, can recruit the adapter proteins Gab1,
Grb2, and Shc and the p85 subunit of phosphatidylinositol-
3-kinase (PI3K) [19]. MET then activates downstream
signaling of the Ras-mitogen-activated protein kinase
(MAPK) and/or PI3K-Akt pathways to promote the invasive
growth characteristic of malignancies and their metastatic
properties. However, MET can be activated independently of
HGF binding through amplification and/or mutation. A
single point mutation in the transducer docking site results
in inhibition of the metastasis function of this signaling
cascade, while preserving its oncogenic transformation
capacity [20].
MACC1 enters this complicated series of signaling upstream
of MET. MET has been proven by Stein et al. [2] to be a
transcriptional target of MACC1. SW 480 colon cancer cell
line transfection and small interfering RNA studies suggest
that the influence of MACC1 on the HGF/MET pathway is
probably independent of MET. Transfection of MACC1 into
cancer cell lines that normally do not express MACC1 led to
increased HGF/MET expression. Small interfering RNA
studies confirmed that MACC1 expression is independent of
MET expression, while silencing of MET expression did not
change MACC1 expression.
H HG GF F/ /M ME ET T   s si ig gn na al li in ng g   a as s   a a   t th he er ra ap pe eu ut ti ic c   t ta ar rg ge et t
Inhibiting HGF/MET signaling is the focus of several
therapeutic strategies for treating epithelial cancers [18].
Several phase I and II trials utilizing direct HGF inhibitors,
and inhibitors of HGF binding to MET, as well as MET
antibodies or small-molecule MET tyrosine kinase inhibitors
are currently under way. The antagonist NK4, which is
composed of an internal fragment of HGF that competitively
binds the HGF receptor of MET without activating MET and
its downstream signaling, has successfully stopped angio-
genesis and tumor growth and metastases in patients with
CRC or pancreatic cancer [21]. In the case of tumors with
HGF-independent MET activation, NK4 is not effective.
AMG102, a humanized anti-HGF antibody that directly
inhibits HGF, is being tried on patients with renal cell
carcinoma and glioblastoma multiforme [22].
Antibodies to the extracellular domain of MET have shown
some success in preclinical models of several tumor types
[23,24]. Several MET tyrosine kinase inhibitors are being
given to gastric cancer patients with tumors harboring MET
amplification. The sensitivity of other cancer-related tyro-
sine kinase inhibitors varies according to the specific
receptor mutations, resulting in mutation-specific binding
affinities; thus, the development of MET tyrosine kinase
inhibitors has been designed to have high-affinity binding
dependent on the variant, in order to decrease resistance to
these agents [25]. Combination therapies with other signal
transduction inhibitors have been tried to increase thera-
peutic effectiveness. Because enhanced transforming growth
factor-α (EGFR) and MET pathways can activate one
another, combination therapy with inhibitors to EGFR and
MET are under evaluation in cancer cell lines [26].
Combination therapy with MET tyrosine kinase inhibitors
and standard chemotherapeutic agents and the anti-EGFR
antibody cetuximab is another treatment modality that
targets the HGF/MET pathway.
M MA AC CC C1 1 a a   r re el li ia ab bl le e   p pr ro og gn no os st ti ic c   i in nd di ic ca at to or r   a an nd d   n ne ew w   t ta ar rg ge et t
f fo or r   t tr re ea at tm me en nt t   o of f   C CR RC C
Although the cellular distribution of MET is a strong
prognostic indicator for survival from colon [27] and breast
cancer [28,29], assays of expression of MET have not been
routinely used for clinical purposes to predict which patients
have the highest risk for CRC recurrence. The results
reported by Stein et al. suggest that MACC1 mRNA expres-
sion is an independent prognostic indicator of recurrence
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Patients with CRC tumors with low MACC1 mRNA had 5-
year survival rates of 80% compared to 15% for those with
high levels of MACC1 mRNA expression [2].
MACC1 mRNA expression may be used in the future for
prognostication and guidance in determining which patients
might most benefit from standard chemotherapeutic
strategies. If MACC1 overexpression is found to be
detectable in serum, stool or urine, it could serve as a marker
of recurrence following CRC surgery and treatment. In
addition, MACC1 inhibitors may be developed to disrupt
aberrant signaling of HGF/MET, thus minimizing tumor
invasion and metastasis and providing benefits to CRC
patients at both the chemopreventive and therapeutic levels.
A Ab bb br re ev vi ia at ti io on ns s
CA, cancer antigen; CEA, carcinoembryonic antigen; CRC,
colorectal cancer; DCC, deleted in colon cancer; EGFR,
enhanced transforming growth factor-α; HGF, hepatocyte
growth factor; MET, HGF receptor proto-oncogene;
AMG102, humanized anti-HGF antibody; MACC1,
metastasis-associated in colon cancer-1; MAPK, Ras-
mitogen-activated protein kinase; SF, scatter factor; TIMP-1,
tissue inhibitor of metalloproteinases.
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